| 2021-12-31 | Linvatec Corporation | $4,272 | Long term medical supply or device loan | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | | 2021 |
| 2021-12-31 | Stryker Corporation | $799 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-12-22 | Gilead Sciences, Inc. | $1,472 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2021 |
| 2021-12-16 | Volta Medical Inc | $4,893 | Research payment | Cash or cash equivalent | VX1 Device, Cardiac Electrophysiology | TailoredAF | 2021 |
| 2021-11-23 | Abbott Laboratories | $12,735 | Research payment | Cash or cash equivalent | Absorb GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2021 |
| 2021-11-23 | Welch Allyn | $985 | Debt forgiveness | Cash or cash equivalent | None Device, Not Applicable | | 2021 |
| 2021-11-19 | Mallinckrodt Hospital Products Inc. | $2,496 | Debt forgiveness | Cash or cash equivalent | OFIRMEV Drug, ACUTE CARE | | 2021 |
| 2021-11-09 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A | 2021 |
| 2021-11-04 | ENDOTRONIX, INC. | $11,500 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2021 |
| 2021-10-28 | Boston Scientific Corporation | $12,735 | Research payment | In-kind items and services | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | LONGEVITY STUDY | 2021 |
| 2021-10-18 | Gilead Sciences, Inc. | $10,065 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-10-18 | Johnson & Johnson Health Care Systems Inc. | $5,285 | Debt forgiveness | In-kind items and services | | | 2021 |
| 2021-10-18 | Johnson & Johnson Health Care Systems Inc. | $1,434 | Debt forgiveness | In-kind items and services | | | 2021 |
| 2021-10-18 | Johnson & Johnson Health Care Systems Inc. | $271 | Debt forgiveness | In-kind items and services | | | 2021 |
| 2021-10-07 | Gilead Sciences, Inc. | $15,925 | Research payment | Cash or cash equivalent | | A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen o | 2021 |
| 2021-09-30 | Novocure Inc. | $8,675 | Research payment | Cash or cash equivalent | | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2021 |
| 2021-09-24 | Abbott Laboratories | $766 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-09-23 | Novocure Inc. | $1,012 | Research payment | Cash or cash equivalent | | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2021 |
| 2021-09-22 | Gilead Sciences, Inc. | $2,066 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2021 |
| 2021-09-16 | Novartis Pharmaceuticals Corporation | $1,000 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and S | 2021 |
| 2021-09-14 | Johnson & Johnson Health Care Systems Inc. | $4,330 | Debt forgiveness | In-kind items and services | | | 2021 |
| 2021-09-13 | Abbott Laboratories | $666 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-09-09 | Novocure Inc. | $7,056 | Research payment | Cash or cash equivalent | | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2021 |
| 2021-09-07 | Boston Scientific Corporation | $916 | Research payment | In-kind items and services | General Tachy Device, Tachy | LONGEVITY STUDY | 2021 |
| 2021-09-07 | Boston Scientific Corporation | $280 | Research payment | In-kind items and services | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | LONGEVITY STUDY | 2021 |
| 2021-09-01 | Volta Medical Inc | $13,100 | Research payment | Cash or cash equivalent | VX1 Device, Cardiac Electrophysiology | TailoredAF | 2021 |
| 2021-08-10 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A | 2021 |
| 2021-08-04 | Gilead Sciences, Inc. | $15,125 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-08-03 | Aesculap, Inc. | $5,343 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $4,000 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $3,072 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $2,136 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $1,984 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $1,547 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $810 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $772 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $344 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-08-03 | Aesculap, Inc. | $233 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-06-23 | Gilead Sciences, Inc. | $1,472 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2021 |
| 2021-06-22 | BIOTRONIK INC. | $1,200 | Consulting Fee | Cash or cash equivalent | Plexa Device, Cardiology/Vascular Diseases | | 2021 |
| 2021-06-09 | Gilead Sciences, Inc. | $16,000 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Incidence of Acute Kidney Disease in COVID-19 Patients Receiving Remdesivir | 2021 |
| 2021-06-02 | Novartis Pharmaceuticals Corporation | $22,522 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) | 2021 |
| 2021-06-02 | Boston Scientific Corporation | $10,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | Using Cardiovascular Implantable Electronic Device Data to Identify Early Indicators of COVID 19 Infection and to Predic | 2021 |
| 2021-05-31 | BIOTRONIK INC. | $1,586 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-05-19 | Gilead Sciences, Inc. | $2,066 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2021 |
| 2021-05-19 | Gilead Sciences, Inc. | $1,032 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-04-30 | BIOTRONIK INC. | $16,138 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-04-27 | Abbott Laboratories | $6,559 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2021 |
| 2021-04-27 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2021 |
| 2021-04-27 | Abbott Laboratories | $600 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2021 |
| 2021-04-27 | Boston Scientific Corporation | $110 | Research payment | In-kind items and services | Energen Device, Tachy | LONGEVITY STUDY | 2021 |
| 2021-04-26 | Gilead Sciences, Inc. | $19,050 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-04-26 | Gilead Sciences, Inc. | $1,269 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2021 |
| 2021-04-14 | Abbott Laboratories | $1,750 | Debt forgiveness | Cash or cash equivalent | | | 2021 |
| 2021-03-23 | Boston Scientific Corporation | $10,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | Using Cardiovascular Implantable Electronic Device Data to Identify Early Indicators of COVID 19 Infection and to Predic | 2021 |
| 2021-03-17 | Gilead Sciences, Inc. | $2,066 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2021 |
| 2021-03-17 | Gilead Sciences, Inc. | $1,134 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-03-14 | PFIZER INC. | $13,496 | Research payment | In-kind items and services | COMIRNATY Biological, VACCINES | A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A | 2021 |
| 2021-02-26 | Novocure Inc. | $3,037 | Research payment | Cash or cash equivalent | | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | $1,801 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | $864 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2021 |
| 2021-02-11 | Abbott Laboratories | $780 | Research payment | Cash or cash equivalent | Absorb GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2021 |
| 2021-01-29 | Johnson & Johnson Health Care Systems Inc. | $944 | Debt forgiveness | In-kind items and services | | | 2021 |
| 2021-01-27 | Novartis Pharmaceuticals Corporation | $10,541 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT | 2021 |
| 2021-01-26 | Abbott Laboratories | $325 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2021 |
| 2021-01-25 | SWEDISH ORPHAN BIOVITRUM AB | $3,670 | Research payment | Cash or cash equivalent | KINERET Drug, IMMUNOLOGY | SOBI.IMMUNO-101 | 2021 |
| 2021-01-20 | Gilead Sciences, Inc. | $8,240 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-01-20 | Gilead Sciences, Inc. | $1,269 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2021 |
Comments